COH – Citi rates the stock as Sell

By Broker News | More Articles by Broker News

A strong first half for Sonova suggests to Citi there may be some downside risk for Cochlear’s earnings assumptions. The broker assumes a significant speech processor upgrade cycle through FY15 and cochlear implant sales growth of 7% in the US

Nevertheless, the stock is considered expensive in both absolute and relative terms and, if market share losses continue, the risk is to the downside, in the broker’s opinion. A Sell rating and $53.21 target are retained.

Sector: Health Care Equipment & Services.

Target price is $53.21.Current Price is $71.45. Difference: ($18.24) – (brackets indicate current price is over target). If COH meets the Citi target it will return approximately -34% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →